![conference banner](/images/conference-banner.jpeg)
Abstract
Background: 2-Furanones have attracted great attention due to their biological activities. They also have the ability to be converted to several biologically active heterocyclic and nonheterocyclic compounds, especially as anti-cancer agents.
Objectives: This research aims to share in the development process of novel cytotoxic agents by synthesizing certain 2-furanone derivatives and using them as starting materials for the preparation of novel heterocyclic and non-heterocyclic compounds, then testing the synthesized derivatives for their anti-cancer activities.
Methods: All the newly synthesized compounds were fully characterized by elemental analysis, IR, Mass, and 1H-NMR spectroscopy. 18 synthesized compounds were selected by National Cancer Institute (NCI) for testing against 60 cell lines, and the active compound was tested as MAPK14 and VEGFR2-inhibitor using Staurosporine as standard.
Results: Compound 3a showed the higher activity against several cell lines; Leukemia (SR), Non- Small Cell Lung Cancer (NCI-H460), colon cancer (HCT-116), ovarian cancer (OVCAR-4), renal cancer (786-0, ACHN and UO-31) and, finally breast cancer (T-47D). It also has better inhibition activity against MAPK14 than the used reference.
Conclusion: Compound 3a has promising anti-cancer activities compared to the used standards and may need further modification and investigations.
Keywords: 2-furanone, 2-pyrrolone, pyridazinone, synthesis, anti-cancer activity, MAPK14 inhibitor.
[http://dx.doi.org/10.1515/hc-2015-0008]
[http://dx.doi.org/10.1016/j.jscs.2014.05.007]
[http://dx.doi.org/10.1016/j.ejmech.2005.03.012] [PMID: 15878219]
[http://dx.doi.org/10.2298/JSC0902103H]
[http://dx.doi.org/10.1016/j.ejmech.2008.10.030] [PMID: 19059680]
[http://dx.doi.org/10.1016/j.jsps.2015.05.002] [PMID: 27829814]
[http://dx.doi.org/10.2478/v10007-012-0037-7] [PMID: 23333891]
[http://dx.doi.org/10.1016/j.ejmech.2006.12.032] [PMID: 17321008]
[http://dx.doi.org/10.1002/ardp.200700043] [PMID: 17562565]
[http://dx.doi.org/10.4067/S0717-97072011000300013]
[http://dx.doi.org/10.1002/jhet.2401]
[http://dx.doi.org/10.1080/00397911.2016.1193755]
[http://dx.doi.org/10.1111/cbdd.13183] [PMID: 29469985]
[http://dx.doi.org/10.1155/2013/926723]
[PMID: 11507069]
[http://dx.doi.org/10.2217/nnm.15.66] [PMID: 26214355]
[http://dx.doi.org/10.1016/j.bmcl.2010.10.128] [PMID: 21084192]
[http://dx.doi.org/10.1016/S1074-5521(00)00025-9] [PMID: 11033082]
[http://dx.doi.org/10.1016/j.bmcl.2013.02.027] [PMID: 23453843]
[http://dx.doi.org/10.1080/1061186X.2019.1703189] [PMID: 31814456]
[http://dx.doi.org/10.1021/jm8001185] [PMID: 18529047]
[http://dx.doi.org/10.1016/j.bioorg.2018.06.003] [PMID: 29920422]
[http://dx.doi.org/10.2174/1871520617666170102152928] [PMID: 28042776]
[http://dx.doi.org/10.9734/ACSJ/2016/23961]
[http://dx.doi.org/10.1038/513481a] [PMID: 25254460]
[http://dx.doi.org/10.1021/jm00120a002] [PMID: 2848124]
[http://dx.doi.org/10.1016/j.cbpa.2010.02.018] [PMID: 20303320]
[http://dx.doi.org/10.3390/ijms21093267] [PMID: 32380742]
[http://dx.doi.org/10.1054/bjoc.2000.1473] [PMID: 11076644]
[http://dx.doi.org/10.1038/nrc1951] [PMID: 16990858]
[http://dx.doi.org/10.1016/j.molcel.2008.05.026]
[http://dx.doi.org/10.1084/jem.20122037] [PMID: 23669395]
[http://dx.doi.org/10.1002/bmc.3370] [PMID: 25424874]
[http://dx.doi.org/10.3978/j.issn.2305-5839.2014.08.14] [PMID: 25568876]
[http://dx.doi.org/10.17628/ecb.2014.3.1064-1068]
![Wayfinder Image](/images/wayfinder.jpg)